NASDAQ:BMRN - BioMarin Pharmaceutical News Headlines

$76.50
+4.77 (+6.65 %)
(As of 08/18/2019 04:00 PM ET)
Today's Range
$72.13
Now: $76.50
$76.68
50-Day Range
$72.65
MA: $80.43
$85.73
52-Week Range
$71.53
Now: $76.50
$106.74
Volume1.83 million shs
Average Volume1.21 million shs
Market Capitalization$13.73 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.35

Headlines

BioMarin Pharmaceutical (NASDAQ BMRN) News Headlines

Source:
DateHeadline
Notable Friday Option Activity: BIIB, BMRN, ELNotable Friday Option Activity: BIIB, BMRN, EL
www.nasdaq.com - August 16 at 5:51 PM
$455.10 Million in Sales Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter$455.10 Million in Sales Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter
www.americanbankingnews.com - August 15 at 1:48 AM
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 31% Discount?Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 31% Discount?
finance.yahoo.com - August 14 at 4:56 PM
 Brokerages Expect BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Will Post Earnings of $0.33 Per Share Brokerages Expect BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Will Post Earnings of $0.33 Per Share
www.americanbankingnews.com - August 13 at 6:36 PM
FY2021 EPS Estimates for BioMarin Pharmaceutical Inc. Raised by Analyst (NASDAQ:BMRN)FY2021 EPS Estimates for BioMarin Pharmaceutical Inc. Raised by Analyst (NASDAQ:BMRN)
www.americanbankingnews.com - August 8 at 10:01 AM
BioMarin's Roller Coaster ContinuesBioMarin's Roller Coaster Continues
finance.yahoo.com - August 6 at 5:36 PM
JPMorgan Chase & Co. Reiterates Buy Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)JPMorgan Chase & Co. Reiterates Buy Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)
www.americanbankingnews.com - August 5 at 9:05 AM
BioMarin (BMRN) Shares Down on Q1 Earnings & Sales MissBioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss
finance.yahoo.com - August 2 at 10:14 PM
Edited Transcript of BMRN earnings conference call or presentation 1-Aug-19 8:30pm GMTEdited Transcript of BMRN earnings conference call or presentation 1-Aug-19 8:30pm GMT
finance.yahoo.com - August 2 at 10:14 PM
BioMarin Pharmaceutical (NASDAQ:BMRN) Announces Quarterly  Earnings ResultsBioMarin Pharmaceutical (NASDAQ:BMRN) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 2 at 8:36 PM
Biomarin Pharmaceutical Inc (BMRN) Q2 2019 Earnings Call TranscriptBiomarin Pharmaceutical Inc (BMRN) Q2 2019 Earnings Call Transcript
finance.yahoo.com - August 2 at 5:08 PM
BioMarin Stock Dropped After Hours on Weak Earnings, but Analysts Aren’t WorriedBioMarin Stock Dropped After Hours on Weak Earnings, but Analysts Aren’t Worried
finance.yahoo.com - August 2 at 10:12 AM
BioMarin Pharmaceutical (BMRN) Lags Q2 Earnings and Revenue EstimatesBioMarin Pharmaceutical (BMRN) Lags Q2 Earnings and Revenue Estimates
finance.yahoo.com - August 1 at 10:40 PM
BioMarin Pharmaceutical EPS misses by $0.09, misses on revenueBioMarin Pharmaceutical EPS misses by $0.09, misses on revenue
seekingalpha.com - August 1 at 5:07 PM
BioMarin Q2 miss pressures shares, down 3% after hoursBioMarin Q2 miss pressures shares, down 3% after hours
seekingalpha.com - August 1 at 5:07 PM
BioMarin Announces Second Quarter 2019 Financial ResultsBioMarin Announces Second Quarter 2019 Financial Results
finance.yahoo.com - August 1 at 5:07 PM
Stock Traders Buy High Volume of BioMarin Pharmaceutical Put Options (NASDAQ:BMRN)Stock Traders Buy High Volume of BioMarin Pharmaceutical Put Options (NASDAQ:BMRN)
www.americanbankingnews.com - August 1 at 9:54 AM
BioMarin Pharmaceutical Q2 2019 Earnings PreviewBioMarin Pharmaceutical Q2 2019 Earnings Preview
seekingalpha.com - July 31 at 10:01 PM
Financial Survey: Akero Therapeutics (NASDAQ:AKRO) versus BioMarin Pharmaceutical (NASDAQ:BMRN)Financial Survey: Akero Therapeutics (NASDAQ:AKRO) versus BioMarin Pharmaceutical (NASDAQ:BMRN)
www.americanbankingnews.com - July 29 at 4:24 PM
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Recommendation of "Buy" from BrokeragesBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 25 at 11:29 AM
BioMarin Pharmaceutical (BMRN) to Release Earnings on ThursdayBioMarin Pharmaceutical (BMRN) to Release Earnings on Thursday
www.americanbankingnews.com - July 25 at 4:26 AM
Health Care Digest: Why 2020 could be big for women's health, Trump's kidney order — and moreHealth Care Digest: Why 2020 could be big for women's health, Trump's kidney order — and more
finance.yahoo.com - July 16 at 5:15 PM
BioMarin to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1 at 4:30pm ETBioMarin to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1 at 4:30pm ET
finance.yahoo.com - July 16 at 9:59 AM
BioMarin Pharmaceutical Inc.s (NASDAQ:BMRN) Shift From Loss To ProfitBioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shift From Loss To Profit
finance.yahoo.com - July 10 at 10:00 AM
JP Morgan: 2 Gene Therapy Stocks to Buy NowJP Morgan: 2 Gene Therapy Stocks to Buy Now
finance.yahoo.com - July 10 at 10:00 AM
BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shift From Loss To ProfitBioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shift From Loss To Profit
finance.yahoo.com - July 10 at 10:00 AM
BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of DirectorsBioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors
finance.yahoo.com - July 9 at 10:34 AM
Biomarin on go with marketing applications for hemophilia A gene therapyBiomarin on go with marketing applications for hemophilia A gene therapy
seekingalpha.com - July 8 at 10:12 AM
BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and EuropeBioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe
finance.yahoo.com - July 8 at 10:12 AM
BioMarin Pharmaceutical: A Robust Fundamental Pick In 2019BioMarin Pharmaceutical: A Robust Fundamental Pick In 2019
seekingalpha.com - July 4 at 10:09 AM
Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?
finance.yahoo.com - July 3 at 4:59 PM
Healthcare: Drugmakers and Providers Look AttractiveHealthcare: Drugmakers and Providers Look Attractive
finance.yahoo.com - July 1 at 4:46 PM
BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019
finance.yahoo.com - June 27 at 10:09 AM
Catalyst Pharmaceuticals: Beaten-Down Orphan Drug Company And A Contrarian BuyCatalyst Pharmaceuticals: Beaten-Down Orphan Drug Company And A Contrarian Buy
seekingalpha.com - June 25 at 4:59 PM
BioMarin Earns Milestone Payments from Pfizer for TALZENNA® (talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA MutationBioMarin Earns Milestone Payments from Pfizer for TALZENNA® (talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
finance.yahoo.com - June 21 at 4:47 PM
Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy licenseChicago biotech sues Third Rock, bluebird bio CEO over gene therapy license
finance.yahoo.com - June 14 at 12:46 PM
Week In Review: Frontage, A U.S.-China CRO, Stages $205 Million Hong Kong IPOWeek In Review: Frontage, A U.S.-China CRO, Stages $205 Million Hong Kong IPO
seekingalpha.com - June 11 at 4:55 PM
Something worth doing: How a biotech entrepreneur grew a 700-person company and is conquering rare diseases'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases
www.bizjournals.com - June 11 at 4:55 PM
'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases
finance.yahoo.com - June 11 at 4:55 PM
Should BioMarin Pharmaceutical (NASDAQ:BMRN) Be Disappointed With Their 32% Profit?Should BioMarin Pharmaceutical (NASDAQ:BMRN) Be Disappointed With Their 32% Profit?
finance.yahoo.com - June 10 at 10:51 AM
BioMarins Vimizim Wins Nod in China for Rare Genetic MaladyBioMarin's Vimizim Wins Nod in China for Rare Genetic Malady
finance.yahoo.com - June 6 at 5:19 PM
BioMarin's Vimizim Wins Nod in China for Rare Genetic MaladyBioMarin's Vimizim Wins Nod in China for Rare Genetic Malady
finance.yahoo.com - June 6 at 5:19 PM
BioMarin to Participate in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 in Rancho Palos Verdes, CABioMarin to Participate in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 in Rancho Palos Verdes, CA
finance.yahoo.com - June 5 at 10:52 AM
BioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A SyndromeBioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome
finance.yahoo.com - June 4 at 11:06 AM
September 20th Options Now Available For BioMarin Pharmaceutical (BMRN)September 20th Options Now Available For BioMarin Pharmaceutical (BMRN)
www.nasdaq.com - June 3 at 4:43 PM
Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?
finance.yahoo.com - June 1 at 10:57 AM
BioMarin Announces Data on Hemophilia Candidate, Shares FallBioMarin Announces Data on Hemophilia Candidate, Shares Fall
finance.yahoo.com - May 29 at 4:55 PM
BioMarin’s 2019 Stock Gains Erased After Release of Gene Therapy DataBioMarin’s 2019 Stock Gains Erased After Release of Gene Therapy Data
www.barrons.com - May 29 at 10:18 AM
Noteworthy Tuesday Option Activity: BHVN, BMRN, ASHNoteworthy Tuesday Option Activity: BHVN, BMRN, ASH
www.nasdaq.com - May 28 at 4:40 PM
This Biotech Had Positive Data In Gene Therapy — But It Wasn't EnoughThis Biotech Had Positive Data In Gene Therapy — But It Wasn't Enough
finance.yahoo.com - May 28 at 4:40 PM
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel